STLN · Starling Oncology, Inc.
$6.54
+0.14 (+2.19%)
At close · Aug 19
Market Cap
$652.26M
Shares
101.92M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Daniel Virnich | — | $1,934,930 |
| Yale Podnos | — | $775,905 |
| Robert Carter | — | $734,130 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Daniel Virnich | — | $1,118,358 |
| Mihir Shah | — | $733,144 |
| Jeremy Castle | — | $622,220 |
| Yale Podnos | — | $610,332 |
| Robert Carter | — | $434,404 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $1,215,190 |
| Daniel Virnich | — | $808,129 |
| Mihir Shah | — | $801,743 |
| Yale Podnos | — | $591,284 |
| Jeremy Castle | — | $486,126 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $6,629,723 |
| Daniel Virnich | — | $3,244,461 |
| Mihir Shah | — | $2,264,237 |
| Yale Podnos | — | $1,249,186 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $11,635,536 |
| Daniel Virnich | — | $7,638,167 |
| Scott Dalgleish | — | $4,758,691 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Brad Hively | — | $611,400 |
| Daniel Virnich | — | $418,684 |
| Scott Dalgleish | — | $317,583 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kimberly Tzoumakas | director | Appointed | 2026-02-23 |
| Mark D. Stolper | Audit Committee Chairman | Appointed | 2026-01-07 |
| Mark D. Stolper | Director | Appointed | 2026-01-07 |
| Gabriel Ling | Board of Directors | Resigned | 2025-12-01 |
| Richard Barasch | Chairman of the Board | Retired | 2025-08-13 |
| Richard Barasch | Board of Directors | Resigned | 2025-08-13 |
| Jeremy Castle | Chief Operating Officer | Resigned | 2025-05-07 |
| Maeve O'Meara | director | Resigned | 2024-11-12 |
| Robert Carter | Chief Financial Officer | Appointed | 2024-09-23 |
| Mihir Shah | Chief Financial Officer, principal financial officer, and principal accounting officer | Resigned | 2024-09-23 |
| Jeremy N. Castle | Chief Operations Officer | Appointed | 2023-09-06 |
| Ravi Sarin | director of the Board | Resigned | 2023-09-01 |
| Daniel Virnich | Chief Executive Officer | Appointed | 2023-06-12 |
| Brad Hively | Chief Executive Officer | Resigned | 2023-06-12 |
| Matthew Miller, M.D. | Chief Operating Officer | Terminated | 2023-05-22 |
| Diona Simoneit | Chief Accounting Officer and principal accounting officer | Resigned | 2022-12-01 |
| Gabriel Ling | Board | Appointed | 2022-09-22 |
| Mark Pacala | Board | Appointed | 2022-09-22 |
| Diona Simoneit | principal accounting officer | Appointed | 2022-04-04 |
| Mihir Shah | Chief Financial Officer | Appointed | 2022-04-04 |
| Dr. Matt Miller | Chief Operating Officer | Appointed | 2022-03-07 |
| Dr. Matthew Miller | Chief Operating Officer | Appointed | 2022-03-07 |
| Dr. Daniel Virnich | President | Appointed | 2022-03-07 |
| Mark Huppelsheuser | General Counsel | Appointed | 2021-11-18 |
| Daniel Virnich | Chief Operating Officer | Appointed | 2021-11-18 |
Key facts
CIK
1799191
CUSIP
68236X100
13F (30d)
128 filings
128 filers
Visit website
Investor relations